Automate Your Wheel Strategy on AMGN
With Tiblio's Option Bot, you can configure your own wheel strategy including AMGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMGN
- Rev/Share 63.4312
- Book/Share 11.5372
- PB 25.7013
- Debt/Equity 9.2446
- CurrentRatio 1.1704
- ROIC 0.0953
- MktCap 159440583120.0
- FreeCF/Share 20.2881
- PFCF 14.6075
- PE 26.8882
- Debt/Assets 0.6421
- DivYield 0.0388
- ROE 0.9294
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AMGN | Guggenheim | -- | Neutral | -- | $288 | May 20, 2025 |
| Resumed | AMGN | Cantor Fitzgerald | -- | Neutral | -- | $305 | April 22, 2025 |
| Resumed | AMGN | BofA Securities | -- | Underperform | -- | $256 | Dec. 10, 2024 |
| Initiation | AMGN | Bernstein | -- | Outperform | -- | $380 | Oct. 17, 2024 |
| Downgrade | AMGN | Truist | Buy | Hold | $320 | $333 | Oct. 14, 2024 |
| Initiation | AMGN | Cantor Fitzgerald | -- | Overweight | -- | $405 | Sept. 27, 2024 |
News
Amgen (AMGN) Outperforms Broader Market: What You Need to Know
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The latest trading day saw Amgen (AMGN) settling at $296.85, representing a +2.18% change from its previous close.
Read More
Final Trades: Amgen, Caterpillar, Honeywell and Freeport-McMoran
Published: July 02, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Amgen's gastric cancer drug meets late-stage trial goal
Published: June 30, 2025 by: Reuters
Sentiment: Positive
Amgen said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.
Read More
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
Read More
Here's Why Amgen (AMGN) is a Strong Growth Stock
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why Amgen (AMGN) is a Strong Value Stock
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
What's Happening With Amgen Stock?
Published: June 24, 2025 by: Forbes
Sentiment: Negative
Amgen stock (NASDAQ:AMGN) fell 6% on Monday, June 23, 2025, after mid-stage clinical trial results for its long-acting experimental obesity drug, MariTide, revealed a need for a low starting dose to mitigate side effects like vomiting. Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase with an eight-week dose escalation period.
Read More
Low start dose of Amgen experimental weight-loss drug limits side effects
Published: June 23, 2025 by: Reuters
Sentiment: Positive
People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as much weight as those given high doses but with milder side effects, according to full results of a mid-stage trial presented at a medical meeting on Monday.
Read More
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvements at 52 Weeks In People Living With Obesity With Type 2 Diabetes, MariTide Demonstrated Up to ~17% Average Weight Loss and Robust HbA1c Improvements Dose Escalation With Lower Starting Doses Substantially Improved Gastrointestinal Tolerability, Without Compromising Efficacy The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep Apnea Will be Initiated in 2025 THOUSAND OAKS, Calif. …
Read More
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Read More
Here's Why Amgen (AMGN) is a Strong Momentum Stock
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Amgen (AMGN) is a Top Growth Stock for the Long-Term
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Read More
Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies
Published: June 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs like MariTide and olpasiran to offset losses. Recent financials show solid revenue growth and improved margins, though net selling prices and legacy drugs like Enbrel remain under pressure. Valuation analysis reveals AMGN is priced for no growth, offering 27% upside if the company achieves even modest revenue increases.
Read More
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
Read More
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Negative
AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.
Read More
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New England Journal of Medicine THOUSAND OAKS, Calif. , June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard-of-care (SOC) chemotherapy in patients with small cell lung cancer (SCLC) who progressed on or after one line of platinum-based chemotherapy (median OS: 13.6 vs 8.3 months; hazard …
Read More
Amgen drug cuts small cell lung cancer death risk by 40%
Published: June 02, 2025 by: Reuters
Sentiment: Positive
Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease had worsened after an initial round of chemo, according to interim data from a late-stage trial presented at a major medical meeting on Monday.
Read More
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Read More
Avoid These Dividend Disasters Before It's Too Late
Published: May 23, 2025 by: Seeking Alpha
Sentiment: Negative
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
Read More
Amgen Inc. (AMGN) RBC Capital Markets Global Healthcare Conference (Transcript)
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Amgen Inc. (NASDAQ:AMGN ) RBC Capital Markets Global Healthcare Conference May 21, 2025 9:00 AM ET Company Participants Justin Claeys - VP, IR Kave Niksefat - Senior Vice President of Global Marketing & Access Conference Call Participants Gregory Renza - RBC Capital Markets Gregory Renza Good morning everyone. Welcome back to 2025 RBC Global Healthcare Conference.
Read More
AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Read More
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.
Read More
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Read More
Amgen CEO Robert A. Bradway to Receive Honorary Degree from KGI
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Claremont, CA, May 08, 2025 (GLOBE NEWSWIRE) -- During the Keck Graduate Institute commencement ceremony on May 17, 2025, Robert A. Bradway will receive an honorary Doctor of Philosophy in Applied Life Sciences degree in recognition of his significant leadership contributions to the biotechnology field.
Read More
Amgen's TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, England--(BUSINESS WIRE)--Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as the first therapy specifically licensed for the treatment of adult patients with moderate-to-severe Thyroid Eye Disease (TED). Affecting approximately 50,000 people in the UK,1 TED is a progressive and potentially vision-threatening condition, which can cause eye bulging, double vision, eye pain, r.
Read More
About Amgen Inc. (AMGN)
- IPO Date 1983-06-17
- Website https://www.amgen.com
- Industry Drug Manufacturers - General
- CEO Robert A. Bradway
- Employees 28000